|
CA1339210C
(en)
|
1988-05-31 |
1997-08-05 |
John Lewicki |
Recombinant techniques for production of novel natriuretic and vasodilator peptides
|
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
|
US6541610B1
(en)
|
1989-09-05 |
2003-04-01 |
Immunex Corporation |
Fusion proteins comprising tumor necrosis factor receptor
|
|
DE69108830T2
(de)
|
1990-04-20 |
1995-09-14 |
Hisayuki Matsuo |
Neue im schwein vorkommende physiologisch aktive peptide.
|
|
JP2930380B2
(ja)
|
1990-07-13 |
1999-08-03 |
壽之 松尾 |
ブタ由来新規生理活性ペプチド(cnp―53)
|
|
JP3026351B2
(ja)
|
1990-07-13 |
2000-03-27 |
壽之 松尾 |
ブタcnp遺伝子及び前駆体蛋白
|
|
JP2977159B2
(ja)
|
1990-09-07 |
1999-11-10 |
壽之 松尾 |
カエル由来新規生理活性ペプチド(カエルcnp)
|
|
JP2977158B2
(ja)
|
1990-09-07 |
1999-11-10 |
壽之 松尾 |
トリ由来新規生理活性ペプチド(ニワトリcnp)
|
|
JP3026352B2
(ja)
|
1990-09-11 |
2000-03-27 |
壽之 松尾 |
ラットCNPcDNA及び前駆体蛋白
|
|
JP3026354B2
(ja)
|
1990-09-27 |
2000-03-27 |
壽之 松尾 |
ヒトcnp遺伝子及び前駆体蛋白
|
|
JP2809533B2
(ja)
|
1991-01-31 |
1998-10-08 |
壽之 松尾 |
Cnp類似体ペプチド
|
|
AU662155B2
(en)
|
1991-05-10 |
1995-08-24 |
Celtrix Pharmaceuticals, Inc. |
Targeted delivery of bone growth factors
|
|
WO1994020534A1
(en)
|
1993-03-03 |
1994-09-15 |
Mayo Foundation For Medical Education And Research |
Vasonatrin peptide and analogs thereof
|
|
ATE304604T1
(de)
|
1993-06-24 |
2005-09-15 |
Frank L Graham |
Adenovirus vektoren für gentherapie
|
|
WO1995005455A1
(en)
|
1993-08-13 |
1995-02-23 |
Rijksuniversiteit Te Groningen |
Pharmaceutical composition comprising phosphatase or a derivative thereof
|
|
BR9407956A
(pt)
|
1993-10-25 |
1996-11-26 |
Canji Inc |
Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais
|
|
CA2174517C
(en)
|
1993-11-12 |
2007-01-02 |
David Lowe |
Receptor specific atrial natriuretic peptides
|
|
US5665704A
(en)
|
1993-11-12 |
1997-09-09 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
|
US5846932A
(en)
|
1993-11-12 |
1998-12-08 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
|
US6525022B1
(en)
|
1993-11-12 |
2003-02-25 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
|
US7252989B1
(en)
|
1994-04-04 |
2007-08-07 |
Board Of Regents, The University Of Texas System |
Adenovirus supervector system
|
|
US5767239A
(en)
|
1994-06-02 |
1998-06-16 |
Boehringer Mannheim Gmbh |
Process for preparing cardiodilatin fragments; highly purified cardiodilatin fragments and intermediate products for the preparation of same
|
|
JPH0870875A
(ja)
|
1994-09-05 |
1996-03-19 |
Tosoh Corp |
組換えアルカリフォスファタ−ゼ融合タンパク質
|
|
US5863782A
(en)
|
1995-04-19 |
1999-01-26 |
Women's And Children's Hospital |
Synthetic mammalian sulphamidase and genetic sequences encoding same
|
|
US6028055A
(en)
|
1996-10-22 |
2000-02-22 |
Genetech, Inc. |
Receptor selective BNP
|
|
CA2269656A1
(en)
|
1996-10-22 |
1998-04-30 |
Genentech, Inc. |
Receptor specific brain natriuretic peptide (bnp)
|
|
WO2000053755A2
(en)
|
1999-03-08 |
2000-09-14 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor
|
|
AU6278298A
(en)
|
1997-02-14 |
1998-09-08 |
Salk Institute For Biological Studies, The |
Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
|
|
EP1062229A1
(en)
|
1998-03-09 |
2000-12-27 |
Zealand Pharmaceuticals A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
|
CA2245903A1
(en)
|
1998-09-28 |
2000-03-28 |
Mcgill University |
Use of pex in the treatment of metabolic bone diseases
|
|
CA2260376A1
(en)
|
1999-02-11 |
2000-08-11 |
Universite De Montreal |
New metalloproteases of the neprilysin family
|
|
CA2262056A1
(en)
|
1999-02-24 |
2000-08-24 |
Guy Boileau |
Composition, methods and reagents for the synthesis of a soluble form of human pex
|
|
JP2002542304A
(ja)
|
1999-04-28 |
2002-12-10 |
ベクトレイムド インコーポレイテッド |
酵素的に活性化された重合薬物接合体
|
|
SI1105409T1
(sl)
|
1999-05-17 |
2006-06-30 |
Conjuchem Inc |
Zascita endogenih peptidov pred peptidazno ucinkovitostjo s konjugacijo na krvne komponente
|
|
US6849714B1
(en)
|
1999-05-17 |
2005-02-01 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
US20040266673A1
(en)
|
2002-07-31 |
2004-12-30 |
Peter Bakis |
Long lasting natriuretic peptide derivatives
|
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
JP2000327583A
(ja)
|
1999-05-17 |
2000-11-28 |
Medei Sci Puraningu:Kk |
骨指向性ホルモン誘導体
|
|
DE19942230C2
(de)
|
1999-09-03 |
2003-09-25 |
Wolf-Georg Forssmann |
Verwendung natriuretischer Peptide als antibiotisch wirksame Subsanzen zur Behandlung von bakteriellen Infektionen
|
|
WO2001036620A2
(en)
|
1999-11-16 |
2001-05-25 |
Genzyme Corporation |
Vectors and transgenies with regulatory elements for gene delivery to the liver
|
|
AU2583901A
(en)
|
1999-12-17 |
2001-06-25 |
Ariad Pharmaceuticals, Inc. |
Proton pump inhibitors
|
|
US6407211B1
(en)
|
1999-12-17 |
2002-06-18 |
Mayo Foundation For Medical Education And Research |
Chimeric natriuretic peptides
|
|
CN1233331C
(zh)
*
|
2000-01-10 |
2005-12-28 |
李世林 |
以头部渗透疗法为主治疗癫痫症的药物
|
|
JP4237375B2
(ja)
|
2000-03-31 |
2009-03-11 |
アスビオファーマ株式会社 |
虚血性疾患の処置又は予防に用いる医薬組成物
|
|
US20050142217A1
(en)
|
2000-04-26 |
2005-06-30 |
Adams Michael A. |
Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
|
|
US7678391B2
(en)
|
2000-04-26 |
2010-03-16 |
Queen's University At Kingston |
Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
|
|
EP1502604A1
(en)
|
2000-04-26 |
2005-02-02 |
Cellegy Pharmaceuticals, Inc |
Use of nitric oxide mimetics in cancer treatment
|
|
IL152428A0
(en)
|
2000-04-26 |
2003-05-29 |
Univ Kingston |
Formulations and method of using nitric oxide mimetics against a malignant cell phenotype
|
|
US6830885B1
(en)
|
2000-08-18 |
2004-12-14 |
Phenogene Therapeutiques Inc. |
Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
|
|
CA2418461A1
(en)
|
2000-08-23 |
2002-02-28 |
Biomep Inc. |
Method and compositions for promoting osteogenesis
|
|
US6436386B1
(en)
|
2000-11-14 |
2002-08-20 |
Shearwater Corporation |
Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
|
|
SK288342B6
(en)
|
2000-12-07 |
2016-03-01 |
Lilly Co Eli |
GLP-1 fusion proteins
|
|
JP2002178279A
(ja)
|
2000-12-12 |
2002-06-25 |
Ulvac Japan Ltd |
基板搬送方法
|
|
AU2002255478A1
(en)
|
2001-01-10 |
2002-09-12 |
Pe Corporation (Ny) |
Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
|
|
JP2002246704A
(ja)
|
2001-02-16 |
2002-08-30 |
Philips Japan Ltd |
電子装置及び回路装置
|
|
IL142118A0
(en)
|
2001-03-20 |
2002-03-10 |
Prochon Biotech Ltd |
Method and composition for treatment of skeletal dysplasias
|
|
US20020183276A1
(en)
|
2001-03-23 |
2002-12-05 |
Burnham Institute |
Compositions and methods for modulating bone mineral deposition
|
|
US7888372B2
(en)
|
2001-03-23 |
2011-02-15 |
National Institutes Of Health (Nih) |
Compositions and methods for modulating bone mineral deposition
|
|
EP1395293B1
(en)
|
2001-05-14 |
2009-07-22 |
Gbp Ip, Llc |
Lentiviral vectors encoding clotting factors for gene therapy
|
|
CA2453434C
(en)
|
2001-07-16 |
2009-04-14 |
Hk Pharmaceuticals, Inc. |
Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
|
|
BRPI0203172B8
(pt)
|
2001-09-28 |
2021-05-25 |
Nakao Kazuwa |
composição farmacêutica para acondroplasia
|
|
US20050202442A1
(en)
|
2003-12-15 |
2005-09-15 |
Morris David W. |
Novel therapeutic targets in cancer
|
|
DE60239763D1
(de)
|
2001-12-20 |
2011-05-26 |
Enobia Pharma Inc |
Knochenpolypeptid-1
|
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
|
WO2003060071A2
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US20030158132A1
(en)
|
2002-01-22 |
2003-08-21 |
Genvec, Inc. |
Method for enhancing bone density or formation
|
|
CA2478145A1
(en)
|
2002-03-06 |
2003-09-12 |
Cellegy Pharmaceuticals, Inc. |
Formulations and methods of using nitric oxide mimetics in cancer treatment
|
|
US20050113286A1
(en)
|
2002-03-18 |
2005-05-26 |
Schreiner George F. |
Methods for treating congestive heart failure
|
|
WO2003079979A2
(en)
|
2002-03-18 |
2003-10-02 |
Scios Inc. |
Method for treating congestive heart failure
|
|
IL149562A0
(en)
|
2002-05-09 |
2002-11-10 |
Prochon Ltd |
Fgf variants and methods for use thereof
|
|
CA2433479A1
(en)
|
2002-07-22 |
2004-01-22 |
F. Hoffmann-La Roche Ag |
Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
|
|
CA2488348A1
(en)
|
2002-07-31 |
2004-02-05 |
Conjuchem Inc. |
Long lasting natriuretic peptide derivatives
|
|
AU2003270427A1
(en)
|
2002-09-06 |
2004-03-29 |
University Of South Florida |
Cellular delivery of natriuretic peptides
|
|
CA2511680A1
(en)
|
2002-11-18 |
2004-06-03 |
Syn X Pharma, Inc. |
Polyclonal-monoclonal elisa assay for detecting n-terminus probnp
|
|
US7648962B2
(en)
|
2002-11-26 |
2010-01-19 |
Biocon Limited |
Natriuretic compounds, conjugates, and uses thereof
|
|
WO2004047871A2
(en)
|
2002-11-26 |
2004-06-10 |
Nobex Corporation |
Modified naturetic compounds, conjugates, and uses thereof
|
|
WO2004050620A2
(en)
|
2002-12-03 |
2004-06-17 |
Enobia Pharma |
Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex
|
|
EP1583554A2
(en)
|
2003-01-13 |
2005-10-12 |
Gudrun Rappold-Hoerbrand |
Use of natriuretic peptides for the treatment of stature disorders related to the shox gene
|
|
WO2004074320A2
(en)
|
2003-02-14 |
2004-09-02 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
|
US7488713B2
(en)
|
2004-03-18 |
2009-02-10 |
University Of South Florida |
Cancer treatment using C-type natriuretic peptides
|
|
JP2006527190A
(ja)
|
2003-04-17 |
2006-11-30 |
サイファージェン バイオシステムズ インコーポレイテッド |
ナトリウム利尿ペプチドに関連したポリペプチド、並びにこれらの同定および使用法
|
|
WO2005007809A2
(en)
|
2003-05-30 |
2005-01-27 |
Alexion Pharmaceuticals, Inc. |
Antibodies and fusion proteins that include engineered constant regions
|
|
US7919255B2
(en)
|
2003-06-17 |
2011-04-05 |
Otago Innovation Limited |
Assessment of skeletal growth using measurements of NT-CNP peptides
|
|
ES2354881T3
(es)
|
2003-06-20 |
2011-03-18 |
Mayo Foundation For Medical Education And Research |
Isoformas de péptido natriurético cerebral.
|
|
WO2005052593A1
(en)
|
2003-10-29 |
2005-06-09 |
The University Of Leicester |
Detection
|
|
US7431915B2
(en)
|
2003-10-31 |
2008-10-07 |
The Regents Of The University Of California |
Peptides whose uptake by cells is controllable
|
|
US7736653B2
(en)
|
2003-11-13 |
2010-06-15 |
Hanmi Pharm. Co., Ltd |
Pharmaceutical composition comprising an immunoglobulin Fc region as a carrier
|
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
|
EP1720562A4
(en)
|
2004-01-15 |
2009-10-28 |
Scios Inc |
METHOD FOR TREATING CARDIAL REMODELING AFTER MYOCARDIAL DAMAGE
|
|
US20080182299A1
(en)
|
2004-01-27 |
2008-07-31 |
Compugent Ltd. |
Novel brain natriuretic peptide variants and methods of use thereof
|
|
AU2005207886A1
(en)
|
2004-01-27 |
2005-08-11 |
Compugen Usa, Inc. |
Novel brain natriuretic peptide variants and methods of use thereof
|
|
WO2005087802A2
(en)
|
2004-03-11 |
2005-09-22 |
Genentech, Inc. |
Process for producing polypeptides
|
|
EP3620530A1
(en)
|
2004-03-31 |
2020-03-11 |
Kazuwa Nakao |
Composition for increasing body height
|
|
KR101207155B1
(ko)
|
2004-03-31 |
2012-12-04 |
카즈와 나카오 |
관절염증 치료제 또는 예방제
|
|
JP2005292718A
(ja)
|
2004-04-05 |
2005-10-20 |
Furukawa Electric Co Ltd:The |
光導波路、光導波路モジュールおよび光導波路の作成方法
|
|
ES2887039T3
(es)
|
2004-04-21 |
2021-12-21 |
Alexion Pharma Inc |
Conjugados para administración ósea y procedimiento de uso de estos para dirigir proteínas al hueso
|
|
SG152290A1
(en)
|
2004-05-04 |
2009-05-29 |
Univ Singapore |
Method for expressing sialylated glycoproteins in mammalian cells and cells thereof
|
|
EP1750728A4
(en)
|
2004-05-10 |
2009-04-29 |
Novacea Inc |
PREVENTION AGAINST ARTERIAL RESTENOSIS USING ACTIVE VITAMIN D COMPOUNDS
|
|
US7863238B2
(en)
|
2004-06-10 |
2011-01-04 |
Saint Louis University |
Proteins with an attached short peptide of acidic amino acids
|
|
US20070081984A1
(en)
|
2005-10-11 |
2007-04-12 |
Shunji Tomatsu |
Compositions and methods for treating hypophosphatasia
|
|
US7972593B2
(en)
|
2004-06-10 |
2011-07-05 |
Saint Louis University |
Delivery of therapeutic agents to the bone
|
|
US20070081986A1
(en)
|
2005-10-07 |
2007-04-12 |
Shunji Tomatsu |
Beta-glucuronidase with an attached short peptide of acidic amino acids
|
|
BRPI0512496A
(pt)
|
2004-06-23 |
2008-03-04 |
Genzyme Corp |
processos e composições para o tratamento de doenças policìsticas
|
|
WO2006005140A2
(en)
|
2004-07-15 |
2006-01-19 |
The University Of Queensland |
Proteinaceous compounds and uses therefor
|
|
US20090142347A1
(en)
|
2004-09-29 |
2009-06-04 |
The Burnham Institute For Medical Research |
Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
|
|
WO2006060641A2
(en)
|
2004-12-01 |
2006-06-08 |
Genzyme Corporation |
Methods for targeted delivery of genetic material to the liver
|
|
PL2510942T3
(pl)
|
2005-04-07 |
2016-02-29 |
Cardiorentis Ag |
Zastosowanie peptydu natriuretycznego do leczenia niewydolności serca
|
|
EP1874816A4
(en)
|
2005-04-26 |
2010-08-25 |
Medimmune Inc |
MODULATION OF THE ANTIBODY EFFECTOR FUNCTION BY "HINGE" DOMENGINE ENGINEERING
|
|
US20070042957A1
(en)
|
2005-08-19 |
2007-02-22 |
Mayo Foundation For Medical Education And Research |
Type v phosphodiesterase inhibitors and natriuretic polypeptides
|
|
US7470668B2
(en)
|
2005-08-24 |
2008-12-30 |
Enobia Pharma Inc. |
Method of use of specific natriuretic peptide receptor c ligands, transgenic non-human mammals expressing specific natriuretic peptide receptor c antagonists and cells thereof
|
|
US20070099831A1
(en)
|
2005-09-06 |
2007-05-03 |
Paul Morley |
Parathyroid hormone analogues and methods of use
|
|
US7803901B2
(en)
|
2005-09-16 |
2010-09-28 |
Mayo Foundation For Medical Education And Research |
Polypeptides with natriuresis activity
|
|
WO2007041645A2
(en)
|
2005-10-03 |
2007-04-12 |
Scios Inc. |
Oxidized human bnp
|
|
RU2316334C2
(ru)
|
2005-12-19 |
2008-02-10 |
Медитек Индастриз ЛЛС |
Способ активации утраченных двигательных функций, а также определения эффективности их восстановления при повреждении центральной нервной системы
|
|
US7625564B2
(en)
|
2006-01-27 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
|
|
DK1987178T3
(en)
|
2006-02-20 |
2015-04-20 |
Phylogica Ltd |
Process for the construction and screening of peptide structure libraries
|
|
US7787945B2
(en)
*
|
2006-03-08 |
2010-08-31 |
Neuropace, Inc. |
Implantable seizure monitor
|
|
US8784833B2
(en)
|
2006-06-27 |
2014-07-22 |
Saint Louis University |
Prenatal enzyme replacement therapy for hypophosphatasia
|
|
US8962697B2
(en)
|
2006-06-30 |
2015-02-24 |
Interface Biologics Inc. |
Bioreponsive polymers
|
|
TW200817431A
(en)
|
2006-08-08 |
2008-04-16 |
Mayo Foundation |
Diuretic and natriuretic polypeptides
|
|
US7825092B2
(en)
|
2006-08-08 |
2010-11-02 |
University Of South Florida |
Dendroaspis natriuretic peptide for treatment of cancer
|
|
EP2295445A1
(en)
|
2006-09-08 |
2011-03-16 |
Mayo Foundation for Medical Education and Research |
Aquaretic and natriuretic polypeptides lacking vasodilatory activity
|
|
EP2615108B1
(en)
|
2006-09-08 |
2016-10-26 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and thier uses
|
|
EP2081602A2
(en)
|
2006-10-25 |
2009-07-29 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
|
US20100168443A1
(en)
|
2006-11-02 |
2010-07-01 |
University Of Virginia Patent Foundation |
Ethoid-Containing Compounds, Methods for Preparing Ethoid-Containing Compounds, and Methods of Use
|
|
US8987200B2
(en)
|
2006-11-16 |
2015-03-24 |
Kai Pharmaceuticals, Inc. |
Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
|
|
KR100856413B1
(ko)
*
|
2006-12-06 |
2008-09-04 |
삼성전자주식회사 |
정착기 및 이를 포함하는 화상형성장치
|
|
US20080181903A1
(en)
|
2006-12-21 |
2008-07-31 |
Pdl Biopharma, Inc. |
Conjugate of natriuretic peptide and antibody constant region
|
|
ATE554395T1
(de)
|
2007-03-12 |
2012-05-15 |
Biomedica Medizinprodukte Gmbh & Co Kg |
Diagnose septischer komplikationen
|
|
EP1985697A1
(en)
|
2007-04-27 |
2008-10-29 |
AM-Pharma B.V. |
Modified phosphatases
|
|
KR20080098216A
(ko)
|
2007-05-04 |
2008-11-07 |
한미약품 주식회사 |
캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
|
|
ES2619332T3
(es)
|
2007-05-11 |
2017-06-26 |
Alexion Pharmaceuticals, Inc. |
Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
|
|
NZ581395A
(en)
|
2007-05-14 |
2012-08-31 |
Biogen Idec Inc |
Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
|
|
EP2162464A1
(en)
|
2007-06-06 |
2010-03-17 |
Boehringer Ingelheim International GmbH |
Natriuretic fusion proteins
|
|
WO2008154543A2
(en)
|
2007-06-11 |
2008-12-18 |
Abbott Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis
|
|
US20110077383A1
(en)
|
2007-07-03 |
2011-03-31 |
Medimmune, Llc |
Hinge domain engineering
|
|
AU2008274845A1
(en)
|
2007-07-06 |
2009-01-15 |
Theratechnologies Inc. |
Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (alpha-MSH) and atrial natriuretic protein (ANP) and uses in hypertension and acute kidney injury
|
|
EP2171053B1
(en)
|
2007-07-20 |
2014-04-23 |
Mayo Foundation for Medical Education and Research |
Natriuretic polypeptides
|
|
US20090053192A1
(en)
|
2007-08-10 |
2009-02-26 |
Burnham Institute For Medical Research |
Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof
|
|
CN103298935A
(zh)
|
2007-08-15 |
2013-09-11 |
阿穆尼克斯公司 |
用于改善生物活性多肽性能的组合物和方法
|
|
RU2010114040A
(ru)
|
2007-09-11 |
2011-10-20 |
Мондобайотек Лабораториз Аг (Li) |
Применение дезлорелина и мастопана в качестве терапевтического средства
|
|
WO2009043457A2
(en)
|
2007-09-11 |
2009-04-09 |
Mondobiotech Laboratories Ag |
Use of a peptide as a therapeutic agent
|
|
EP2185183B1
(en)
|
2007-09-11 |
2016-03-16 |
Cardiopep Pharma GmbH |
Use of natriuretic peptides for treating angioedema syndromes
|
|
RU2010114017A
(ru)
|
2007-09-11 |
2011-10-20 |
Мондобайотек Лабораториз Аг (Li) |
Терапевтическое применение натрийуретического пептида в-типа и гормона роста человека 1-43
|
|
KR20100056509A
(ko)
|
2007-09-11 |
2010-05-27 |
몬도바이오테크 래보래토리즈 아게 |
치료제로서의 펩티드의 용도
|
|
JP5395794B2
(ja)
|
2007-09-11 |
2014-01-22 |
モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト |
治療剤としてのガラニンペプチドの使用
|
|
US8357656B2
(en)
|
2007-09-15 |
2013-01-22 |
Mayo Foundation For Medical Education And Research |
Natriuretic peptide receptor-C agonists
|
|
AR069409A1
(es)
|
2007-11-21 |
2010-01-20 |
Biomarin Pharm Inc |
Variantes de peptidos natriureticos de tipo c
|
|
WO2009086126A2
(en)
|
2007-12-21 |
2009-07-09 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides
|
|
CN101322866A
(zh)
*
|
2008-01-11 |
2008-12-17 |
梁树立 |
脑深部癫痫放电引导治疗方法与设备
|
|
EP2080812A1
(en)
|
2008-01-18 |
2009-07-22 |
Transmedi SA |
Compositions and methods of detecting post-stop peptides
|
|
PL2277890T3
(pl)
|
2008-05-23 |
2016-06-30 |
Daiichi Sankyo Co Ltd |
Peptyd zdolny do wydłużenia czasu półtrwania w osoczu peptydu będącego przedmiotem zainteresowania
|
|
CA2727085A1
(en)
|
2008-06-06 |
2009-12-10 |
Mayo Foundation For Medical Education And Research |
Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling
|
|
WO2009156481A1
(en)
|
2008-06-25 |
2009-12-30 |
Ascendis Pharma As |
Pegylated bnp
|
|
US20100015144A1
(en)
|
2008-06-26 |
2010-01-21 |
Acceleron Pharma Inc. |
Methods for dosing an activin-actriia antagonist and monitoring of treated patients
|
|
EP2307447B1
(en)
|
2008-07-02 |
2016-03-09 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides with unique pharmacologic profiles
|
|
RU2483081C2
(ru)
|
2008-07-23 |
2013-05-27 |
Ханми Сайенс Ко.,Лтд.,Kr |
Полипептидный комплекс, содержащий непептидильный полимер, обладающий тремя функциональными концами
|
|
US20100093678A1
(en)
|
2008-10-10 |
2010-04-15 |
The University Of Georgia Research Foundation, Inc |
Compositions and methods of the treatment of obesity and osteoporosis
|
|
US8642550B2
(en)
|
2008-10-24 |
2014-02-04 |
Mayo Foundation For Medical Education And Research |
Chimeric natriuretic peptides without hypotensive inducing capability
|
|
WO2010078325A2
(en)
|
2008-12-29 |
2010-07-08 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides for reducing or preventing restenosis
|
|
WO2010082804A2
(en)
|
2009-01-19 |
2010-07-22 |
Hanmi Pharm. Co., Ltd. |
Method for producing physiologically active protein or peptide using immunoglobulin fragment
|
|
EP2413969A4
(en)
|
2009-03-30 |
2012-09-05 |
Boehringer Ingelheim Int |
FUSION PROTEINS WITH DOG FC ELEMENTS
|
|
US20120053123A1
(en)
|
2009-05-05 |
2012-03-01 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides having mutations within their disulfide rings
|
|
DK2432489T3
(en)
|
2009-05-20 |
2017-01-16 |
Biomarin Pharm Inc |
VARIETIES OF C-TYPE NATRIURETIC PEPTID
|
|
US8685024B2
(en)
|
2010-04-14 |
2014-04-01 |
Arrowhead Medical Device Technologies, Llc |
Intramedullary fixation device and methods for bone fixation and stabilization
|
|
KR20130118203A
(ko)
*
|
2010-04-30 |
2013-10-29 |
알렉시온 파마 인터내셔널 에스에이알엘 |
매트릭스 무기물화 장애의 처리방법, 조성물 및 키트
|
|
CA2823066A1
(en)
|
2010-12-27 |
2012-07-05 |
Alexion Pharma International Sarl |
Compositions comprising natriuretic peptides and methods of use thereof
|
|
SG11201401605QA
(en)
|
2011-10-19 |
2014-09-26 |
Alexion Pharma Holding |
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
|
|
EP2776129B2
(en)
|
2011-11-10 |
2020-06-17 |
Kai Pharmaceuticals, Inc. |
Compositions for use in the treatment of chronic kidney disease-mineral bone disorder characterized by soft tissue calcification
|
|
US10052366B2
(en)
|
2012-05-21 |
2018-08-21 |
Alexion Pharmaceuticsl, Inc. |
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
|
|
JP2015526423A
(ja)
|
2012-07-25 |
2015-09-10 |
サイオクサス セラピューティクス リミテッド |
カヘキシア及びサルコペニアを治療するためのs−ピンドロールの使用
|
|
WO2014186809A2
(en)
|
2013-05-17 |
2014-11-20 |
The Translational Genomics Research Institute |
A genetic test to predict patient response to bone morphogenetic protein in arthrodesis
|
|
EP3425048A1
(en)
|
2014-01-24 |
2019-01-09 |
AM-Pharma B.V. |
Chimeric alkaline phosphatase-like proteins
|
|
ES2688066T3
(es)
|
2014-01-24 |
2018-10-30 |
Am-Pharma B.V. |
Procesamiento para recuperación y purificación de una fosfatasa alcalina
|
|
EP3845245B1
(en)
|
2014-06-09 |
2025-06-25 |
Ultragenyx Pharmaceutical Inc. |
The effective and efficient control of serum phosphate for optimal bone formation
|
|
WO2016007873A1
(en)
|
2014-07-11 |
2016-01-14 |
The Regents Of The University Of Michigan |
Compositions and methods for treating craniosynostosis
|
|
EP3207132B1
(en)
|
2014-10-15 |
2019-07-31 |
Alexion Pharmaceuticals, Inc. |
Methods of shifting an isoelectric profile of a protein product and uses thereof
|
|
ES3038086T3
(en)
|
2014-12-05 |
2025-10-09 |
Alexion Pharma Inc |
Treating seizure with recombinant alkaline phosphatase
|
|
EP3250227A2
(en)
|
2015-01-28 |
2017-12-06 |
Alexion Pharmaceuticals, Inc. |
Methods of treating a subject with an alkaline phosphatase deficiency
|
|
KR101867134B1
(ko)
|
2015-03-23 |
2018-06-12 |
한양대학교 산학협력단 |
포유류 세포를 이용하여 목적 물질을 고효율로 생산하기 위한 세포 배양 배지, 이를 이용한 세포 배양 방법 및 목적 물질의 생산 방법
|
|
RU2745528C2
(ru)
|
2015-08-17 |
2021-03-26 |
Алексион Фармасьютикалз, Инк. |
Производство щелочных фосфатаз
|
|
JP6868617B2
(ja)
|
2015-09-28 |
2021-05-12 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
低ホスファターゼ血症の組織非特異的アルカリホスファターゼ(tnsalp)酵素補充療法に有効な投薬計画の特定
|
|
JP2018533571A
(ja)
|
2015-10-30 |
2018-11-15 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
患者の頭蓋縫合早期癒合症を治療するための方法
|
|
US11065306B2
(en)
|
2016-03-08 |
2021-07-20 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in children
|
|
US11186832B2
(en)
|
2016-04-01 |
2021-11-30 |
Alexion Pharmaceuticals, Inc. |
Treating muscle weakness with alkaline phosphatases
|
|
WO2017171871A1
(en)
|
2016-04-01 |
2017-10-05 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in adolescents and adults
|
|
US10898549B2
(en)
|
2016-04-01 |
2021-01-26 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in adolescents and adults
|
|
US10988744B2
(en)
|
2016-06-06 |
2021-04-27 |
Alexion Pharmaceuticals, Inc. |
Method of producing alkaline phosphatase
|
|
ES2887573T3
(es)
|
2016-06-27 |
2021-12-23 |
Alexion Pharma Inc |
Métodos para el tratamiento de la hipofosfatasia en niños y adolescentes
|
|
WO2018035420A1
(en)
|
2016-08-18 |
2018-02-22 |
Alexion Pharmaceuticals, Inc. |
Methods for treating tracheobronchomalacia
|
|
WO2018164995A1
(en)
|
2017-03-09 |
2018-09-13 |
Alexion Pharmaceuticals, Inc . |
Glycoprotein manufacturing process
|